Storm Therapeutics raised $56M in a Series C round announced on April 16, 2026. A biotechnology company developing small molecule drugs that target RNA modifying enzymes for the treatment of cancer.
A biotechnology company developing small molecule drugs that target RNA modifying enzymes for the treatment of cancer.
Storm Therapeutics, based in Cambridge, United Kingdom, announced $56M in Series C financing on April 16, 2026.
Participants include IP Group PLC, UTokyo Innovation Platform Co., M Ventures, Taiho Ventures LLC, Fast Track Initiative (FTI), Pfizer Ventures.
Cloudsmith provides hosted software package management for development and DevOps teams.
The deep tech company from Alzenau, founded in 2014 by Peter Geigle, is focusing on an alternative to lithium-ion batteries.
Hypervision Surgical develops computer-assisted tissue analysis tools for surgeons.